Leukapheresis Market Size & Growth Forecast 2027–2036, By Segments (Application, Product Type, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Leukapheresis Market size was valued at USD 255.21 million in 2026 and is anticipated to grow at a 10.5% CAGR from 2027 to 2036, crossing USD 692.66 million by 2036. The industry revenue for 2027 is estimated at USD 277.77 million.
Get more details on this report
Request Free Sample ReportLeukapheresis Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for a 39.07% share in 2026, supported by established apheresis infrastructure, specialized centers, and strong procedural adoption across healthcare settings.
- Asia Pacific is projected to grow at a 12.21% CAGR, driven by expanding healthcare capacity, advanced blood collection adoption, and increasing access to specialized centers.
Segment Momentum
- Research Application held a 74.54% market share in 2026 due to its established role in cell isolation, sample preparation, and laboratory workflows requiring consistent, high-quality white blood cell collection.
- Leukapheresis Disposables are the fastest-growing product type because every procedure requires new disposable components, creating continuous demand that rises alongside expanding research and clinical procedure volumes.
Market Expansion Drivers
- Rising prevalence of leukemia and autoimmune disorders increasing demand for leukapheresis procedures.
- Advancements in automated leukapheresis systems improving collection efficiency and patient safety outcomes.
- Growing adoption of CAR-T cell therapies expanding demand for high-quality cell collection technologies.
Leading Market Participants
- Prominent players in the leukapheresis market include Terumo BCT, Inc. (United States), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (United States), Miltenyi Biotec GmbH (Germany), Charles River Laboratories International, Inc. (United States), Lonza Group AG (Switzerland), Asahi Kasei Medical Co., Ltd. (Japan), Macopharma SA (France), Grifols, S.A. (Spain).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 255.21 million
- 2027 Estimated Market Size: USD 277.77 million.
- Projected Market Size: USD 692.66 million by 2036
- Growth Forecast: 10.5% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Research Application (Application) | Leukapheresis Devices (Product Type) | Hospitals & Clinics (End-use)
- Emerging Opportunity Segment: Therapeutics Application (Application) | Leukapheresis Disposables (Product Type) | Pharmaceutical & Biotechnology Companies (End-use)
Market Growth Drivers and Industry Trends
Rising prevalence of leukemia and autoimmune disorders increasing demand for leukapheresis procedures
Rising prevalence of leukemia and autoimmune disorders will drive the leukapheresis market growth by increasing the need for procedures that selectively remove abnormal or excessive white blood cells from circulation. Leukapheresis can serve as an important supportive intervention in clinical situations involving elevated leukocyte levels and may help manage complications associated with certain hematological conditions. Growing patient volumes, together with greater awareness of specialized blood component separation procedures, are encouraging healthcare facilities to maintain access to leukapheresis capabilities for patients requiring rapid cellular reduction or therapeutic blood processing.
Advancements in automated leukapheresis systems improving collection efficiency and patient safety outcomes
Advancements in automated leukapheresis systems are improving the leukapheresis market through enhanced control over blood component separation, collection, and monitoring during procedures. Modern systems can automate several operational steps, allowing healthcare professionals to manage cellular collection with greater consistency while supporting precise processing parameters. Improved monitoring and system controls can also help reduce procedural variability and support patient safety, making automated platforms increasingly suitable for hospitals and specialized treatment centers handling complex hematological cases.
Growing adoption of CAR-T cell therapies expanding demand for high-quality cell collection technologies
Growing adoption of CAR-T cell therapies will propel the leukapheresis market by increasing the need for reliable collection of high-quality T cells that can subsequently undergo laboratory processing and genetic modification. Leukapheresis provides a critical initial step in many cell therapy workflows because the quality and composition of collected cellular material can influence downstream manufacturing processes. As personalized cellular therapies become more integrated into oncology treatment pathways, healthcare providers require dependable collection technologies capable of obtaining suitable patient-derived cells while maintaining controlled handling throughout the procedure.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of leukemia and autoimmune disorders increasing demand for leukapheresis procedures | 1.90% | High | North America, Asia Pacific | High | Near Term |
| Advancements in automated leukapheresis systems improving collection efficiency and patient safety outcomes | 1.70% | Moderate | Europe, North America | Medium | Mid Term |
| Growing adoption of CAR-T cell therapies expanding demand for high-quality cell collection technologies | 1.50% | High | North America, Europe | Emerging | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
The leukapheresis market was led by North America, which accounted for 39.07% of the market share in 2026, reflecting advanced blood-processing infrastructure, sophisticated healthcare systems, and established use of apheresis technologies in specialized clinical settings. Demand is supported by the growing utilization of leukapheresis in therapeutic procedures, cellular therapies, and blood-component management. Strong clinical expertise, specialized treatment facilities, and continued investment in advanced medical technologies contribute to the region’s established market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing regional market, supported by improving healthcare infrastructure, increasing adoption of advanced blood-processing procedures, and expanding access to specialized therapies. Greater investment in hospitals and transfusion services is strengthening the availability of apheresis capabilities, while growing awareness of cellular and blood-based treatments is encouraging broader clinical adoption. Improvements in healthcare delivery and the development of specialized treatment centers are expected to further support regional demand for leukapheresis technologies.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
Germany 🇩🇪
Precision Treatment IntegrationGermany integrates leukapheresis into specialized clinical care supported by advanced transfusion medicine and research networks. The country prioritizes standardized procedures and high-quality collection systems that support expanding cellular therapy and therapeutic apheresis applications.
France 🇫🇷
Specialized Care ExpansionFrance advances leukapheresis use through specialized hospitals and collaborative research programs focused on oncology and immune disorders. The market favors technologies that enhance procedural consistency while supporting evolving therapeutic protocols.
Italy 🇮🇹
Hospital-Based AdoptionItaly continues expanding leukapheresis capabilities within major medical centers managing hematological diseases and transplant procedures. Healthcare providers seek dependable systems that improve operational efficiency and accommodate increasing demand for advanced therapeutic interventions.
Japan 🇯🇵
Regenerative Medicine SupportJapan aligns leukapheresis adoption with its strong regenerative medicine ecosystem and clinical research activities. Healthcare providers focus on reliable cell collection platforms that meet stringent quality expectations while supporting personalized treatment development.
South Korea 🇰🇷
Cell Therapy InfrastructureSouth Korea strengthens leukapheresis demand through expanding biotechnology investments and commercial cell therapy production. The country encourages healthcare facilities to adopt efficient collection systems that support both clinical applications and manufacturing requirements.
United States 🇺🇸
Clinical Innovation HubThe U.S. emphasizes wider adoption of leukapheresis across cell therapy manufacturing, hematology, and immunology applications. Hospitals, research institutions, and biopharmaceutical companies continue investing in advanced collection technologies that improve workflow efficiency and product consistency.
Leukapheresis Market Share (%), by Application, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportApplication Segment Analysis: Research Application (Largest Segment) vs Therapeutics Application (Fastest-Growing Segment)
Research application accounted for the largest share of 74.54% in 2026 in the leukapheresis market, reflecting the extensive use of leukapheresis in scientific and translational research involving blood components and cellular therapies. The procedure enables researchers to obtain specific cell populations for laboratory investigation, disease modeling, and development of advanced treatment approaches. Growing interest in cellular biology and immune-related research is supporting continued utilization of leukapheresis as a tool for generating high-quality cellular material for research activities.
Therapeutics application is experiencing faster growth as leukapheresis becomes increasingly relevant to cell-based and immune-focused treatment strategies. The ability to collect and process targeted cellular components supports therapeutic workflows where patient-derived cells are required for subsequent treatment development or administration. Expanding interest in personalized cellular therapies and advanced immunological approaches is strengthening the clinical relevance of leukapheresis and broadening its role beyond conventional research applications.
Product Type Segment Analysis: Leukapheresis Devices (Largest Segment) vs Leukapheresis Disposables (Fastest-Growing Segment)
The leukapheresis market was dominated by leukapheresis devices, which captured the largest share of 67.05% in 2026. These systems are fundamental to the collection and separation of specific blood components, making them central to both research and therapeutic workflows. Increasing use of cellular processing technologies requires reliable equipment capable of supporting efficient and controlled leukocyte collection, while advances in automated processing and system performance are helping strengthen adoption across specialized healthcare settings.
Leukapheresis disposables are expanding more rapidly as the growing use of leukapheresis procedures increases demand for single-use components that support safe and efficient cellular collection. Disposable kits and related consumables can help reduce cross-contamination risks and simplify procedure preparation while supporting standardized workflows. Their importance is particularly evident in settings where cell-processing procedures require stringent handling practices, contributing to broader adoption alongside the increasing utilization of leukapheresis technologies.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Application | Research Application, Therapeutics Application | Research Application | Therapeutics Application |
| Product Type | Leukapheresis Devices, Leukapheresis Disposables | Leukapheresis Devices | Leukapheresis Disposables |
| End-use | Blood Centers, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics | Hospitals & Clinics | Pharmaceutical & Biotechnology Companies |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Leading companies in the leukapheresis market:
1. Terumo BCT Inc. (United States)
2. Fresenius SE & Co. KGaA (Germany)
3. Haemonetics Corporation (United States)
4. Miltenyi Biotec GmbH (Germany)
5. Charles River Laboratories International Inc. (United States)
6. Lonza Group AG (Switzerland)
7. Asahi Kasei Medical Co. Ltd. (Japan)
8. Macopharma SA (France)
9. Grifols S.A. (Spain)
The leukapheresis market is witnessing strategic expansion driven by rising demand for cell-based therapies and advanced blood component separation technologies. Companies are enhancing automated collection systems and improving workflow efficiency to support growing applications in immunotherapy and regenerative medicine. Consolidation activities and investments in specialized treatment infrastructure are also contributing to stronger competitive positioning within the market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Terumo BCT Inc. (United States) | |||||||
| Fresenius SE & Co. KGaA (Germany) | |||||||
| Haemonetics Corporation (United States) | |||||||
| Miltenyi Biotec GmbH (Germany) | |||||||
| Charles River Laboratories International Inc. (United States) | |||||||
| Lonza Group AG (Switzerland) | |||||||
| Asahi Kasei Medical Co. Ltd. (Japan) | |||||||
| Macopharma SA (France) | |||||||
| Grifols S.A. (Spain). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Bristol Myers Squibb | Mar-24 | The FDA approved Breyanzi, a CAR-T cell therapy for specific leukemia and lymphoma indications. The therapy utilizes a leukapheresis-based collection process to harvest patient white blood cells, reinforcing the essential role of leukapheresis equipment and procedure standardization in the clinical manufacturing and supply chain of personalized cell-based immunotherapies. |
| Terumo Blood and Cell Technologies | Aug-23 | The FDA approved the Reveos Automated Whole Blood Processing System, which enables the efficient separation of whole blood into white blood cells and other components. This automated technology enhances blood processing capabilities and supply chain resilience for clinical cell collection, supporting the growing demand for high-quality source material in downstream cell and gene therapy manufacturing. |
| Akadeum Life Sciences | May-23 | Akadeum Life Sciences launched a specialized product line utilizing BACS Microbubble technology to streamline the isolation of T cells and PBMCs from leukapheresis material. By eliminating the need for traditional centrifugation and lysis steps, this innovation reduces processing time and enhances cell viability, addressing critical workflow inefficiencies in research-grade cell therapy development. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Leukapheresis Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Indication | Leukemia & Lymphoma, Sickle Cell Disease, Stem Cell Collection, Cellular Therapy Manufacturing, Other Hematological Conditions |
| Cell Type Collected | Leukocytes, Hematopoietic Stem & Progenitor Cells, T Cells, Mononuclear Cells |
| Procedure Type | Therapeutic Leukapheresis, Donor Leukapheresis, Cellular Therapy Collection, Research-Grade Cell Collection |
Leukapheresis Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Cell Therapy Manufacturing Demand Assessment |
|
| Apheresis Center Expansion Strategy |
|
| Clinical Application Opportunity Mapping |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How large is the leukapheresis market?
What is the anticipated CAGR of the leukapheresis industry?
How are rising hematologic disorder treatment needs driving leukapheresis market expansion?
How are automated systems and cell therapy trends influencing leukapheresis technology adoption?
Why is Research Application the leading segment in the leukapheresis market?
Which product type is growing fastest in the leukapheresis market?
Why does North America hold the largest leukapheresis market share?
What is driving Asia Pacific growth in the leukapheresis market?
Who holds a significant market share in the leukapheresis landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook